Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AKYA Stock Forecast 2026-2027
$1.29
Current Price
$64.44M
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to AKYA Price Targets
+39.5%
To High Target of $1.80
+27.9%
To Median Target of $1.65
-16.3%
To Low Target of $1.08
AKYA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-53.3%
1 Year Change
0.0%
Year-to-Date Change
-62.3%
From 52W High of $3.42
+38.6%
From 52W Low of $0.93
📊 TOP ANALYST CALLS
Did AKYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Akoya is one of their latest high-conviction picks.
Latest AKYA Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, AKYA has a neutral consensus with a median price target of $1.65 (ranging from $1.08 to $1.80). The overall analyst rating is Buy (6.0/10). Currently trading at $1.29, the median forecast implies a 27.9% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 39.5% upside. Conversely, the most conservative target is provided by Kyle Mikson at Canaccord Genuity, suggesting a 16.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AKYA Analyst Ratings
0
Buy
6
Hold
0
Sell
AKYA Price Target Range
Low
$1.08
Average
$1.65
High
$1.80
Current: $1.29
Latest AKYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AKYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $1.08 |
| Apr 29, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $1.80 |
| Apr 14, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $1.65 |
| Mar 25, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Downgrade | $1.80 |
| Mar 18, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $3.50 |
| Nov 19, 2024 | Piper Sandler | David Westenberg | Overweight | Reiterates | $3.00 |
| Nov 15, 2024 | Craig-Hallum | Bill Bonello | Hold | Downgrade | $5.00 |
| Nov 15, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.50 |
| Aug 13, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $4.00 |
| Aug 6, 2024 | JP Morgan | Rachel Vatnsdal | Neutral | Downgrade | $N/A |
| Aug 6, 2024 | Craig-Hallum | Bill Bonello | Buy | Maintains | $7.00 |
| Aug 6, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Downgrade | $3.00 |
| Aug 6, 2024 | BTIG | Mark Massaro | Neutral | Downgrade | $N/A |
| Jun 3, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $4.00 |
| May 14, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $6.00 |
| May 14, 2024 | BTIG | Mark Massaro | Buy | Maintains | $6.00 |
| Mar 6, 2024 | JP Morgan | Tycho Peterson | Overweight | Maintains | $10.00 |
| Mar 5, 2024 | UBS | John Sourbeer | Buy | Maintains | $7.50 |
| Mar 5, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Reiterates | $10.00 |
| Dec 14, 2023 | Guggenheim | Subbu Nambi | Neutral | Initiates | $N/A |
Akoya Biosciences, Inc. (AKYA) Competitors
The following stocks are similar to Akoya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Akoya Biosciences, Inc. (AKYA) Financial Data
Valuation Metrics
Market Cap
$64.44M
Enterprise Value
$121.02M
P/E Ratio
N/A
PEG Ratio
-2.3x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
-9.3%
Gross Margin
+59.3%
Operating Margin
-79.7%
Net Margin
-59.4%
EPS Growth
-9.3%
Financial Health
Cash/Price Ratio
+42.8%
Current Ratio
0.6x
Debt/Equity
-14.2x
ROE
-354.3%
ROA
-17.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Akoya Biosciences, Inc. (AKYA) Business Model
About Akoya Biosciences, Inc.
What They Do
Develops spatial biology solutions for precision medicine.
Business Model
Akoya Biosciences generates revenue by providing a range of products including software, reagents, and instruments that facilitate high-resolution spatial analysis in various biomedical fields. Their solutions cater to research in oncology, immunology, and neuroscience, supporting drug discovery and translational research.
Additional Information
The company plays a significant role in the spatial biology market, contributing to advancements in understanding disease mechanisms and therapeutic responses, which are crucial for the future of personalized healthcare strategies.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
205
CEO
Mr. Brian McKelligon
Country
United States
IPO Year
2021
Website
www.akoyabio.comAkoya Biosciences, Inc. (AKYA) Latest News & Analysis
Latest News
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. has been featured in a news release dated June 20, 2025. Further details on the context were not provided.
Why It Matters
The mention of a former Attorney General could signal potential legal developments or regulatory changes affecting businesses in Louisiana, impacting market sentiment and investment strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
7 months ago
Quick Summary
Kent Lake PR LLC, holding 6.9% of Quanterix (NASDAQ: QTRX), criticized the company's amended merger terms with Akoya Biosciences (NASDAQ: AKYA), which bypass shareholder votes and involve significant cash and share issuance.
Why It Matters
Kent Lake's statement indicates shareholder dissent regarding Quanterix's merger strategy, potentially impacting stock performance and investor confidence amid an unsolicited offer for Akoya.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced its financial results for Q1 2025, ending March 31. Further details on performance were not provided in the excerpt.
Why It Matters
Akoya's Q1 financial results reveal performance trends, impacting stock valuation and investor sentiment regarding the company's growth and market position in spatial biology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Akoya Biosciences (AKYA) reported a quarterly loss of $0.32 per share, worse than the estimated loss of $0.29, but an improvement from a loss of $0.35 per share a year ago.
Why It Matters
Akoya's larger-than-expected quarterly loss signals potential struggles in meeting market expectations, which may negatively impact investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Kahn Swick & Foti, LLC is investigating the proposed sale of Akoya Biosciences (AKYA) to Quanterix (QTRX), where Akoya shareholders would receive 0.318 QTRX shares per AKYA share.
Why It Matters
The investigation into Akoya's sale to Quanterix could impact shareholder value and raise concerns about the fairness of the deal, influencing investor sentiment and stock prices.
Source: Business Wire
Market Sentiment:
Neutral
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
8 months ago
Quick Summary
Akoya (AKYA) is not expected to meet key criteria for a potential earnings beat in its upcoming report, indicating possible challenges ahead for investors.
Why It Matters
Akoya's lack of key indicators for an earnings beat may signal weak financial performance, potentially impacting stock price and investor confidence ahead of the report.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About AKYA Stock
What is Akoya Biosciences, Inc.'s (AKYA) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Akoya Biosciences, Inc. (AKYA) has a median price target of $1.65. The highest price target is $1.80 and the lowest is $1.08.
Is AKYA stock a good investment in 2026?
According to current analyst ratings, AKYA has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AKYA stock?
Wall Street analysts predict AKYA stock could reach $1.65 in the next 12 months. This represents a 27.9% increase from the current price of $1.29. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Akoya Biosciences, Inc.'s business model?
Akoya Biosciences generates revenue by providing a range of products including software, reagents, and instruments that facilitate high-resolution spatial analysis in various biomedical fields. Their solutions cater to research in oncology, immunology, and neuroscience, supporting drug discovery and translational research.
What is the highest forecasted price for AKYA Akoya Biosciences, Inc.?
The highest price target for AKYA is $1.80 from Kyle Mikson at Canaccord Genuity, which represents a 39.5% increase from the current price of $1.29.
What is the lowest forecasted price for AKYA Akoya Biosciences, Inc.?
The lowest price target for AKYA is $1.08 from Kyle Mikson at Canaccord Genuity, which represents a -16.3% decrease from the current price of $1.29.
What is the overall AKYA consensus from analysts for Akoya Biosciences, Inc.?
The overall analyst consensus for AKYA is neutral. Out of 12 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $1.65.
How accurate are AKYA stock price projections?
Stock price projections, including those for Akoya Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 12:39 AM UTC